This page tracks congressional stock trading activity in Compass Therapeutics, Inc. (CMPX) in the Healthcare sector. Disclosed Capitol has indexed 3 disclosed congressional trades involving CMPX. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of March 2026 — Disclosed Capitol has tracked 3 disclosed congressional trades in Compass Therapeutics, Inc. (CMPX) — 2:1 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Feb 24, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Feb 10, 2023 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Jan 6, 2020 | Phil Roe | R | Sell | $1,001 - $15,000 |
Across the 3 disclosed congressional trades in Compass Therapeutics, Inc. (CMPX), members of Congress have reported 1 buy and 2 sells. The average 30-day alpha vs. the S&P 500 is 4.86%.
As of September 2026, corporate insiders at Compass Therapeutics, Inc. have filed 1 SEC Form 4 transaction in CMPX over the past 12 months — including 1 open-market buy worth $3K.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-09-24 | Lerner Neil — Chief Accounting Officer | Purchase | $3K |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
For fiscal year 2025, Compass Therapeutics, Inc. reported revenue of $850K and net income of -$49.4M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $0, net income -$36.5M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.